BAM-15 (BAM15)
Mitochondrial Uncoupler | Metabolic Enhancer
Community Research
Join others researching BAM-15 — share findings, ask questions, and learn from real experiences
BAM-15 is a synthetic mitochondrial uncoupler that has emerged as a promising research compound for obesity and metabolic disorders. Unlike traditional uncouplers like DNP which have serious toxicity concerns, BAM-15 demonstrates a superior safety profile while effectively increasing energy expenditure and fat oxidation. Research in mice shows BAM-15 reduces body fat without affecting food intake, lean mass, or body temperature. It is approximately 7-fold more potent than DNP and does not induce the dangerous hyperthermia associated with older uncouplers. Note: BAM-15 is a small molecule compound, not a peptide, but is commonly sold alongside peptide products.
BAM-15 targets the inner mitochondrial membrane, enhancing proton permeability and dissipating the proton gradient. This uncouples electron transport from ATP synthesis, forcing mitochondria to increase respiration and burn more substrates (particularly fat) to maintain energy production. BAM-15 activates AMP-activated protein kinase (AMPK) in response to ATP depletion, promoting glucose uptake and fatty acid oxidation. It also activates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), enhancing mitochondrial biogenesis. Unlike DNP or FCCP, BAM-15 does not depolarize plasma membranes or induce apoptosis at effective concentrations, explaining its improved safety profile.
Molecular Data
C16H10F2N6O Complex or non-standard sequence format
Research Indications
Reduces body fat by increasing energy expenditure and fat oxidation without reducing food intake.
Research shows reversal of diet-induced insulin resistance in mouse models.
Addresses multiple components of metabolic syndrome through enhanced energy expenditure.
2024 research shows combining BAM-15 with semaglutide produces stronger metabolic benefits than either alone by countering metabolic adaptation.
May help overcome weight loss plateaus by preventing metabolic adaptation/efficiency.
Research shows decreased liver triglycerides in treated animals.
Improved glucose tolerance observed in research models.
Dosing Protocols
BAM-15 is orally bioavailable and is typically administered as an oral supplement in tablet or capsule form. Research in mice used dietary supplementation (0.1% of diet) or oral gavage dosing. Human dosing protocols are still being established through ongoing research. The compound has a relatively short half-life, which researchers are working to improve through structural modifications.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Metabolic enhancement | 25-50 mg | Once or twice daily | Oral |
| Research protocol (mouse equivalent) | ~10 mg/kg | Daily | Oral gavage |
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- Generally well-tolerated in research
- Possible mild increase in body temperature (less than DNP)
Stop Signs - Discontinue if:
- Significant hyperthermia/overheating
- Excessive sweating
- Rapid heart rate
- Difficulty breathing
Contraindications
- Hyperthyroidism or thyroid disorders
- Heart conditions
- Pregnancy or breastfeeding
- Use of other mitochondrial uncouplers (DNP, FCCP)
- Fever or active infection
Quality Checklist
Good Signs
- White to off-white powder or tablets
- Certificate of analysis with purity >98%
- Proper packaging protected from light
- Reputable supplier
Warning Signs
- No third-party testing available
- Unclear sourcing
Bad Signs
- Discolored product
- No purity information
- Unknown origin
References
Related Peptides
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.